These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31104991)

  • 1. Immune checkpoint blockade for treating progressive multifocal leukoencephalopathy.
    Hohlfeld R
    Lancet Neurol; 2019 Jul; 18(7):623-624. PubMed ID: 31104991
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating.
    Carson KR; Bennett CL
    Leuk Lymphoma; 2009 Mar; 50(3):323-4. PubMed ID: 19347724
    [No Abstract]   [Full Text] [Related]  

  • 3. [Molecular targeted therapy and progressive multifocal leukoencephalopathy].
    Takao M
    Nihon Rinsho; 2015 Sep; 73 Suppl 7():869-76. PubMed ID: 26480807
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel treatments for progressive multifocal leukoencephalopathy.
    Bennett KM; Fernandes PM
    Br J Hosp Med (Lond); 2020 Jul; 81(7):1-9. PubMed ID: 32730143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease.
    Calabrese LH; Molloy ES; Huang D; Ransohoff RM
    Arthritis Rheum; 2007 Jul; 56(7):2116-28. PubMed ID: 17599729
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
    Keene DL; Legare C; Taylor E; Gallivan J; Cawthorn GM; Vu D
    Can J Neurol Sci; 2011 Jul; 38(4):565-71. PubMed ID: 21672696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy.
    Medrano C; Vergez F; Mengelle C; Faguer S; Kamar N; Del Bello A
    Emerg Infect Dis; 2019 Nov; 25(11):2145-2147. PubMed ID: 31625858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
    Cortese I; Muranski P; Enose-Akahata Y; Ha SK; Smith B; Monaco M; Ryschkewitsch C; Major EO; Ohayon J; Schindler MK; Beck E; Reoma LB; Jacobson S; Reich DS; Nath A
    N Engl J Med; 2019 Apr; 380(17):1597-1605. PubMed ID: 30969503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody therapy and progressive multifocal leukoencephalopathy.
    Jackson AC
    Can J Neurol Sci; 2011 Jul; 38(4):545-6. PubMed ID: 21672693
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab.
    Rauer S; Marks R; Urbach H; Warnatz K; Nath A; Holland S; Weiller C; Grimbacher B
    N Engl J Med; 2019 Apr; 380(17):1676-1677. PubMed ID: 30969507
    [No Abstract]   [Full Text] [Related]  

  • 11. Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab.
    Martinot M; Ahle G; Petrosyan I; Martinez C; Gorun DM; Mohseni-Zadeh M; Fafi-Kremer S; Tebacher-Alt M
    Emerg Infect Dis; 2018 Aug; 24(8):1594-1596. PubMed ID: 30016251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy.
    Venniyoor A
    Saudi J Kidney Dis Transpl; 2019; 30(4):998-999. PubMed ID: 31464264
    [No Abstract]   [Full Text] [Related]  

  • 13. Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab.
    Tuccori M; Focosi D; Maggi F; Cosottini M; Meini B; Lena F; Blandizzi C; Del Tacca M; Petrini M
    Ann Hematol; 2010 May; 89(5):519-22. PubMed ID: 19727726
    [No Abstract]   [Full Text] [Related]  

  • 14. Natalizumab and PML.
    Ransohoff RM
    Nat Neurosci; 2005 Oct; 8(10):1275. PubMed ID: 16189528
    [No Abstract]   [Full Text] [Related]  

  • 15. [Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies].
    Takao M
    Brain Nerve; 2013 Nov; 65(11):1363-74. PubMed ID: 24200614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late-Onset Progressive Multifocal Leukoencephalopathy (PML) and Lymphoma in a 65-Year-Old Patient with XIAP Deficiency.
    Seguier J; Briantais A; Ebbo M; Meunier B; Aurran T; Coze S; Kaphan E; De Sainte Marie B; Sbihi Z; Latour S; Cerf-Bensussan N; Picard C; Vély F; Barlogis V; Schleinitz N
    J Clin Immunol; 2021 Nov; 41(8):1975-1978. PubMed ID: 34580798
    [No Abstract]   [Full Text] [Related]  

  • 17. Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma.
    Kranick SM; Mowry EM; Rosenfeld MR
    Neurology; 2007 Aug; 69(7):704-6. PubMed ID: 17698796
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab.
    Walter O; Treiner E; Bonneville F; Mengelle C; Vergez F; Lerebours F; Delobel P; Liblau R; Martin-Blondel G;
    N Engl J Med; 2019 Apr; 380(17):1674-1676. PubMed ID: 30969500
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and immunologic effects of maraviroc in progressive multifocal leukoencephalopathy.
    Middel A; Arends JE; van Lelyveld SF; Otto S; Schuurman R; Frijns CJ; Tesselaar K; Hoepelman AI
    Neurology; 2015 Jul; 85(1):104-6. PubMed ID: 26041329
    [No Abstract]   [Full Text] [Related]  

  • 20. Progressive multifocal leukoencephalopathy.
    Weissert R
    J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.